BE2021C552I2 - - Google Patents
Info
- Publication number
- BE2021C552I2 BE2021C552I2 BE2021C552C BE2021C552C BE2021C552I2 BE 2021C552 I2 BE2021C552 I2 BE 2021C552I2 BE 2021C552 C BE2021C552 C BE 2021C552C BE 2021C552 C BE2021C552 C BE 2021C552C BE 2021C552 I2 BE2021C552 I2 BE 2021C552I2
- Authority
- BE
- Belgium
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
- A61K39/39525—Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72197405P | 2005-09-30 | 2005-09-30 | |
| GBGB0519923.7A GB0519923D0 (en) | 2005-09-30 | 2005-09-30 | Interleukin-13 antibody composition |
| PCT/GB2006/003650 WO2007036745A2 (en) | 2005-09-30 | 2006-09-29 | Interleukin-13 antibody composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2021C552I2 true BE2021C552I2 (enExample) | 2026-01-14 |
Family
ID=37434894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2021C552C BE2021C552I2 (enExample) | 2005-09-30 | 2021-11-22 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20080248048A1 (enExample) |
| EP (1) | EP1942939B2 (enExample) |
| JP (2) | JP2009510046A (enExample) |
| KR (1) | KR101363777B1 (enExample) |
| AU (1) | AU2006296399B2 (enExample) |
| BE (1) | BE2021C552I2 (enExample) |
| BR (1) | BRPI0616359B8 (enExample) |
| CA (1) | CA2623429C (enExample) |
| CY (2) | CY1120874T1 (enExample) |
| FI (1) | FIC20210042I1 (enExample) |
| FR (1) | FR21C1055I2 (enExample) |
| GB (1) | GB2430883B (enExample) |
| HU (1) | HUS2100053I1 (enExample) |
| IL (3) | IL189983A (enExample) |
| LT (1) | LTC1942939I2 (enExample) |
| LU (1) | LUC00239I2 (enExample) |
| NL (1) | NL301143I2 (enExample) |
| NO (2) | NO344859B1 (enExample) |
| PL (1) | PL1942939T5 (enExample) |
| SI (1) | SI1942939T2 (enExample) |
| WO (1) | WO2007036745A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8420086B2 (en) * | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
| MX361174B (es) | 2003-12-23 | 2018-11-29 | Genentech Inc | Anticuerpos anti-il13 novedosos y sus usos. |
| EP2532677A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
| CN102391358B (zh) | 2006-04-05 | 2016-08-10 | 艾伯维生物技术有限公司 | 抗体纯化 |
| JP5419709B2 (ja) * | 2007-01-09 | 2014-02-19 | ワイス・エルエルシー | 抗ｉｌ−１３抗体製剤およびその使用 |
| AU2008269086B2 (en) * | 2007-06-25 | 2014-06-12 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| US20100189721A1 (en) * | 2007-07-06 | 2010-07-29 | Smithkline Beecham Corporation | Antibody formulations |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| NZ601815A (en) | 2008-03-31 | 2014-10-31 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
| GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| NZ599100A (en) | 2009-10-20 | 2014-07-25 | Abbvie Inc | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography |
| KR101615420B1 (ko) | 2010-12-16 | 2016-04-26 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
| WO2012125775A1 (en) | 2011-03-16 | 2012-09-20 | Sanofi | Uses of a dual v region antibody-like protein |
| BR112013025845A2 (pt) * | 2011-04-07 | 2018-09-04 | Glaxosmithkline Llc | formulações com viscosidade reduzida |
| SG10201505454SA (en) * | 2011-07-13 | 2015-09-29 | Abbvie Inc | Methods and compositions for treating asthma using anti-il-13 antibodies |
| AU2012332767C1 (en) | 2011-10-31 | 2017-02-02 | Genentech, Inc. | Antibody formulations |
| WO2013148232A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
| PL3044323T3 (pl) | 2013-09-13 | 2022-06-27 | F.Hoffmann-La Roche Ag | Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych |
| SG11201601823TA (en) | 2013-09-13 | 2016-04-28 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
| JP6715767B2 (ja) | 2013-10-23 | 2020-07-01 | ジェネンテック， インコーポレイテッド | 好酸球性疾患の診断及び治療方法 |
| JP2014062100A (ja) * | 2013-11-05 | 2014-04-10 | Glaxosmithkline Llc | 抗体処方 |
| JP2017507939A (ja) | 2014-02-21 | 2017-03-23 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用 |
| JP6156962B2 (ja) | 2014-02-27 | 2017-07-05 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | エキソソームを単離するための方法および組成物 |
| EP3129497B1 (en) | 2014-04-11 | 2021-09-08 | Novartis AG | Methods of selectively treating asthma using il-13 antagonists |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| JP6247241B2 (ja) * | 2015-02-27 | 2017-12-13 | ノバルティス アーゲー | 抗体処方 |
| EP3271723A1 (en) | 2015-03-16 | 2018-01-24 | F. Hoffmann-La Roche AG | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
| WO2017139290A1 (en) * | 2016-02-10 | 2017-08-17 | Medimmune, Llc | Tralokinumab delivery device |
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| TWI787203B (zh) | 2016-09-23 | 2022-12-21 | 美商建南德克公司 | Il-13拮抗劑用於治療異位性皮炎之用途 |
| CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| KR20220098056A (ko) | 2018-02-09 | 2022-07-08 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
| MX2021004356A (es) | 2018-10-18 | 2021-05-31 | Merck Sharp & Dohme Llc | Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas. |
| MA54089A (fr) | 2018-10-31 | 2022-02-09 | Merck Sharp & Dohme | Anticorps anti-pd-1 humain et procédés d'utilisation associés |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| JP7503056B6 (ja) | 2018-11-07 | 2024-07-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤 |
| WO2020219943A1 (en) | 2019-04-26 | 2020-10-29 | Prolynx Llc | Slow-release cytokine conjugates |
| EP4126943B1 (en) | 2020-03-23 | 2026-04-22 | MedImmune Limited | Methods for treating atopic dermatitis and related disorders |
| CA3097453A1 (en) | 2020-03-23 | 2021-09-23 | Medimmune Limited | Methods for treating atopic dermatitis and related disorders |
| CA3217029A1 (en) | 2021-05-30 | 2022-12-08 | Biolojic Design Ltd. | Engineered dual binding antibodies and uses thereof |
| GB202108379D0 (en) | 2021-06-11 | 2021-07-28 | Medlmmune Ltd | Methods for treating a topic dermatitis and related disorders |
| KR20240046243A (ko) | 2021-08-16 | 2024-04-08 | 메디뮨 엘엘씨 | 항-il-13 항체 제제 |
| IL311027A (en) | 2021-09-15 | 2024-04-01 | Dermira Inc | Il-13 inhibitors for the treatment of prurigo nodularis |
| EP4408885A1 (en) | 2021-09-28 | 2024-08-07 | MedImmune Limited | Methods for treating atopic dermatitis and related disorders |
| CN122374333A (zh) | 2023-12-14 | 2026-07-10 | 德米拉公司 | 用于治疗慢性鼻窦炎伴鼻息肉的il-13抗体 |
| AU2024399620A1 (en) | 2023-12-14 | 2026-05-14 | Dermira, Inc. | Il-13 antibodies for the treatment of perennial allergic rhinitis |
| TW202600591A (zh) | 2024-03-01 | 2026-01-01 | 美商德米拉股份有限公司 | 用於治療發炎後皮膚色素過多或色素過少之ｉｌ—１３抗體 |
| WO2026086810A1 (zh) * | 2024-10-22 | 2026-04-30 | 海南先声药业有限公司 | 抗il-13抗体及其应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU217099B (hu) | 1991-03-29 | 1999-11-29 | Elf Sanofi Sa. | Eljárás citokin típusú aktivitással rendelkező fehérje, azt kódoló rekombináns DNS-szekvencia és a megfelelő transzformált sejtek és mikroorganizmusok előállítására |
| FR2685919B1 (fr) * | 1992-01-08 | 1994-04-08 | Elf Sanofi | Proteine a activite de type cytokine, adn recombinant codant pour cette proteine, cellules animales transformees. |
| US5596072A (en) | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
| JPH07267994A (ja) * | 1994-03-31 | 1995-10-17 | Snow Brand Milk Prod Co Ltd | 新規蛋白質及びその製造法 |
| JP3414856B2 (ja) * | 1994-08-09 | 2003-06-09 | 株式会社ヤトロン | ジフェニルエーテル化合物の免疫学的測定方法 |
| US5866154A (en) † | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
| US6428788B1 (en) * | 1995-03-15 | 2002-08-06 | Penn State University | Compositions and methods for specifically targeting tumors |
| BR9708910A (pt) † | 1996-05-04 | 1999-08-03 | Zeneca Ltd | Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento |
| GB9610992D0 (en) * | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
| ATE230277T1 (de) | 1997-06-13 | 2003-01-15 | Genentech Inc | Stabilisierte antikörperformulierung |
| US6991790B1 (en) * | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| ID27417A (id) † | 1998-06-09 | 2001-04-05 | Statens Seruminstitut | Proses untuk memproduksi immunoglobulin untuk pemberian melalui intravena dan produk-produk immunoglobulin lainnya |
| JP3537331B2 (ja) * | 1998-11-17 | 2004-06-14 | 積水化学工業株式会社 | Ｉｖ型コラーゲンの免疫測定法及び試薬 |
| GB2361704C (en) † | 2000-03-03 | 2006-08-02 | Cambridge Antibody Tech | Human antibodies against eotaxin and their use |
| EP1175931A1 (en) † | 2000-07-25 | 2002-01-30 | Computer Cell Culture Center S.A. | Integration of high cell density bioreactor operation with ultra fast on-line downstream processing |
| WO2003010512A2 (en) † | 2001-07-23 | 2003-02-06 | Accurate Polymers, Inc. | High-speed, solid-liquid separation |
| US20030235555A1 (en) | 2002-04-05 | 2003-12-25 | David Shealey | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
| US20040234499A1 (en) † | 2001-10-26 | 2004-11-25 | David Shealy | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
| US20040248260A1 (en) | 2001-10-26 | 2004-12-09 | Heavner George A. | IL-13 mutein proteins, antibodies, compositions, methods and uses |
| JP2005512522A (ja) * | 2001-10-26 | 2005-05-12 | セントカー・インコーポレーテツド | Ｉｌ−１３ムテインタンパク質、抗体、組成物、方法および使用 |
| AU2003251592A1 (en) * | 2002-06-21 | 2004-01-06 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
| WO2004076485A1 (en) † | 2003-02-28 | 2004-09-10 | Lonza Biologics Plc. | Antibody purification by protein a and ion exchange chromatography |
| US20060257972A1 (en) † | 2003-03-31 | 2006-11-16 | Takashi Ishihara | Purification of human monoclonal antibody and human polyclonal antibody |
| PT1610820E (pt) * | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
| MX361174B (es) † | 2003-12-23 | 2018-11-29 | Genentech Inc | Anticuerpos anti-il13 novedosos y sus usos. |
| CN1234725C (zh) † | 2004-04-07 | 2006-01-04 | 陈志南 | 一种高效快速纯化制备片段抗体的方法 |
| AR049390A1 (es) † | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| CA2577631A1 (en) * | 2004-08-20 | 2006-03-02 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
| WO2006055638A2 (en) * | 2004-11-17 | 2006-05-26 | Abgenix, Inc. | Fully human monoclonal antibodies to il-13 |
| US20060171943A1 (en) * | 2005-02-01 | 2006-08-03 | Amgen Inc. | Compositions and methods of treating fibrotic disorders |
| EP2652038A1 (en) † | 2010-10-14 | 2013-10-23 | Ticona GmbH | Plasticized polyoxymethylene |
-
2006
- 2006-09-29 KR KR1020087010374A patent/KR101363777B1/ko active Active
- 2006-09-29 EP EP06794604.6A patent/EP1942939B2/en active Active
- 2006-09-29 PL PL06794604T patent/PL1942939T5/pl unknown
- 2006-09-29 AU AU2006296399A patent/AU2006296399B2/en active Active
- 2006-09-29 BR BRPI0616359A patent/BRPI0616359B8/pt active IP Right Grant
- 2006-09-29 CA CA2623429A patent/CA2623429C/en not_active Expired - Fee Related
- 2006-09-29 GB GB0619204A patent/GB2430883B/en active Active
- 2006-09-29 WO PCT/GB2006/003650 patent/WO2007036745A2/en not_active Ceased
- 2006-09-29 US US12/067,120 patent/US20080248048A1/en not_active Abandoned
- 2006-09-29 JP JP2008532878A patent/JP2009510046A/ja active Pending
- 2006-09-29 SI SI200632277T patent/SI1942939T2/sl unknown
-
2008
- 2008-03-06 IL IL189983A patent/IL189983A/en active IP Right Grant
- 2008-04-23 NO NO20081946A patent/NO344859B1/no active Protection Beyond IP Right Term
-
2010
- 2010-12-13 US US12/966,377 patent/US9107945B2/en active Active
-
2013
- 2013-10-10 JP JP2013212846A patent/JP5820450B2/ja active Active
- 2013-12-17 IL IL230005A patent/IL230005A/en active IP Right Grant
-
2015
- 2015-07-14 US US14/798,685 patent/US10358488B2/en active Active
-
2016
- 2016-07-10 IL IL246674A patent/IL246674B/en active IP Right Grant
-
2018
- 2018-07-20 CY CY181100758T patent/CY1120874T1/el unknown
-
2021
- 2021-11-03 NL NL301143C patent/NL301143I2/nl unknown
- 2021-11-05 CY CY2021033C patent/CY2021033I1/el unknown
- 2021-11-09 LU LU00239C patent/LUC00239I2/fr unknown
- 2021-11-12 NO NO2021050C patent/NO2021050I1/no unknown
- 2021-11-16 FR FR21C1055C patent/FR21C1055I2/fr active Active
- 2021-11-17 LT LTPA2021528C patent/LTC1942939I2/lt unknown
- 2021-11-22 BE BE2021C552C patent/BE2021C552I2/nl unknown
- 2021-11-23 FI FIC20210042C patent/FIC20210042I1/fi unknown
- 2021-12-02 HU HUS2100053C patent/HUS2100053I1/hu unknown